The APOE Genotype in Idiopathic Normal Pressure Hydrocephalus

Prior research has shown a strong association between the APOE ε4 allele and Alzheimer's disease risk. However, it remains unclear whether this genetic factor influences idiopathic normal-pressure hydrocephalus (iNPH) similarly. Established knowledge includes the role of amyloid plaques in iNPH pathology, but no prior work had resolved how APOE genotype might contribute to this condition. This gap motivated the current investigation into whether APOE ε4 frequency differs in iNPH patients compared to controls. The uncertainty around shared genetic risk factors between iNPH and AD drove the need for this comparative analysis. No prior work had resolved whether iNPH patients carry APOE ε4 at higher rates than the general population. The absence of clear evidence on this point created a need for population-based studies. This uncertainty highlights the importance of distinguishing iNPH from AD in terms of genetic risk profiles. Understanding these differences could improve diagnostic accuracy and treatment approaches.

The aim of this study was to compare APOE genotype frequencies in iNPH patients with those in age-matched controls and Alzheimer's disease patients. The specific problem addressed is whether the APOE ε4 allele contributes to iNPH risk in a manner similar to its role in AD. This investigation sought to clarify if iNPH patients exhibit a higher prevalence of APOE ε4 than the general population. The motivation stems from the observed amyloid plaques in iNPH brains and the known role of APOE ε4 in AD. The study aimed to determine if APOE genotype is a shared risk factor between these two neurological conditions. The researchers proposed that iNPH might involve similar genetic mechanisms as AD. This study sought to test that hypothesis using a population-based control group. The goal was to provide evidence for or against the role of APOE ε4 in iNPH pathophysiology.

The study used a population-based design to compare APOE genotype frequencies across three groups. The first group consisted of 77 iNPH patients diagnosed clinically and confirmed by imaging. The second group included 691 patients with Alzheimer's disease. The third group was a control population of 638 age-matched individuals from the INTERGENE cohort. Genotyping was performed to determine the distribution of APOE alleles in each group. The researchers calculated odds ratios to assess the association between APOE ε4 and iNPH. They compared these odds ratios to those observed in the AD group. Statistical methods included 95% confidence intervals to evaluate the significance of findings. The study controlled for age and sex to ensure accurate comparisons between groups.

The APOE distribution in iNPH patients did not differ significantly from that in the control population. The per-e4-allele odds ratio for iNPH was 0.90 with a 95% confidence interval of (0.50, 1.60). This value was not statistically significant and suggested no increased risk of iNPH with APOE ε4. In contrast, the per-allele odds ratio for Alzheimer's disease was 5.34 (4.10, 7.00), indicating a strong association. The researchers found no evidence that iNPH patients had a higher APOE ε4 frequency than controls. The confidence interval for iNPH included 1, suggesting no meaningful deviation from the general population. The results showed that APOE ε4 was not a distinguishing factor in iNPH compared to AD. These findings highlight the limited role of APOE genotype in iNPH pathophysiology.

The authors concluded that the APOE ε4 allele does not appear to increase the risk of idiopathic normal-pressure hydrocephalus. Their findings suggest that iNPH patients do not differ from the general population in terms of APOE genotype distribution. The per-e4-allele odds ratio for iNPH was not significantly different from 1. The researchers stated that the APOE-related risk of AD in iNPH patients is not higher than in the general population. These conclusions were based on the observed odds ratios and confidence intervals. The authors proposed that iNPH may not share the same genetic risk profile as Alzheimer's disease. Their findings indicate that APOE ε4 is not a significant contributor to iNPH pathology. The study supports the view that iNPH and AD may involve distinct genetic mechanisms.